FOLH1 and breast cancer: All patients had [68 Ga]Ga-PSMA-11 PET/CT at baseline (≤ 6 weeks before the first RLT cycle) and at interim staging (6–8 weeks after the second RLT cycle) allowing for longitudinal BC assessment.